Abstract

COVID-19 vaccines are indispensable, with the number of cases and mortality still rising, and currently no medicines are routinely available for reducing morbidity and mortality, apart from dexamethasone, although others are being trialed and launched. To date, only a limited number of vaccines have been given emergency use authorization by the US Food and Drug Administration and the European Medicines Agency. There is a need to systematically review the existing vaccine candidates and investigate their safety, efficacy, immunogenicity, unwanted events, and limitations. The review was undertaken by searching online databases, i.e., Google Scholar, PubMed, and ScienceDirect, with finally 59 studies selected. Our findings showed several types of vaccine candidates with different strategies against SARS-CoV-2, including inactivated, mRNA-based, recombinant, and nanoparticle-based vaccines, are being developed and launched. We have compared these vaccines in terms of their efficacy, side effects, and seroconversion based on data reported in the literature. We found mRNA vaccines appeared to have better efficacy, and inactivated ones had fewer side effects and similar seroconversion in all types of vaccines. Overall, global variant surveillance and systematic tweaking of vaccines, coupled with the evaluation and administering vaccines with the same or different technology in successive doses along with homologous and heterologous prime-booster strategy, have become essential to impede the pandemic. Their effectiveness appreciably outweighs any concerns with any adverse events.

Highlights

  • The current pandemic of coronavirus disease-19 (COVID-19) caused by Severe AcuteRespiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the seventh human coronavirus discovered [1]

  • According to a clinical trial linked to the Moderna vaccine, SAEs accounted for 26.73 percent of all adverse events (AEs) recorded in the VigiBase, with death occurring in 1.23% of all SAEs

  • We have found that vaccines developed using mRNA technology show overall better efficacy than the other strategies

Read more

Summary

Introduction

The current pandemic of coronavirus disease-19 (COVID-19) caused by Severe Acute. Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the seventh human coronavirus discovered [1]. The virus rapidly spreads in the pharynx and shedding before symptoms occur [38,45,46] Because of these characteristics, the viral load of SARS-CoV-2 is significantly higher than other respiratory viruses [47,48]. We sought to review the current vaccine candidates, focusing on their development strategy, adverse events, and effectiveness based on the published findings, as we have been aware there has been considerable misinformation regarding COVID-19 and its prevention and treatment, increasing morbidity, mortality, and costs [65,96,97,98,99,100]

Methodology
Current Vaccine Candidates
Inactivated Vaccine
Viral Vector-Based Vaccine
Nanoparticle-Based Peptide Vaccine
Efficiency of Vaccines Observed after Phase 3 Trial
Overall Comparison of Vaccine Candidates in the Trial Phase
Gender-Based Adverse Events of COVID-19 Vaccines
Importance of the Integration of Diagnostic Assays Pre- and Post-Vaccination
Mix-and-Match Approach
Genomic Surveillance and Vaccine Up-Gradation
10. Conclusions and Future Directions
Findings
11. Limitation of the Study
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call